MX2024010045A - Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras. - Google Patents
Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras.Info
- Publication number
- MX2024010045A MX2024010045A MX2024010045A MX2024010045A MX2024010045A MX 2024010045 A MX2024010045 A MX 2024010045A MX 2024010045 A MX2024010045 A MX 2024010045A MX 2024010045 A MX2024010045 A MX 2024010045A MX 2024010045 A MX2024010045 A MX 2024010045A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- compounds
- mutant proteins
- quinazoline compounds
- kras mutant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación proporciona compuestos útiles para la inhibición de KRAS G12D, G12V, G12A, G12S o G12C. Los compuestos tienen una fórmula general I: (ver Fórmula) en el que las variables de la Fórmula I se definen en el presente documento. Esta divulgación también proporciona composiciones farmacéuticas que comprenden los compuestos, usos de los compuestos y composiciones para el tratamiento de, por ejemplo, el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310915P | 2022-02-16 | 2022-02-16 | |
| PCT/US2023/062687 WO2023159086A1 (en) | 2022-02-16 | 2023-02-15 | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010045A true MX2024010045A (es) | 2024-08-26 |
Family
ID=85685573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010045A MX2024010045A (es) | 2022-02-16 | 2023-02-15 | Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4479401A1 (es) |
| CN (1) | CN118974055A (es) |
| AU (1) | AU2023222076A1 (es) |
| MX (1) | MX2024010045A (es) |
| WO (1) | WO2023159086A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| NZ749959A (en) | 2016-07-12 | 2024-12-20 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| JP7240320B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としてのピリジン化合物 |
| AR110740A1 (es) | 2017-01-23 | 2019-05-02 | Revolution Medicines Inc | Compuestos bicíclicos como inhibidores alostéricos de shp2 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| MX2020002502A (es) | 2017-09-08 | 2020-07-20 | Amgen Inc | Inhibidores de kras g12c y metodos para utilizarlos. |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| KR20210106474A (ko) | 2018-12-20 | 2021-08-30 | 암젠 인크 | Kif18a 억제제 |
| JP2022514268A (ja) | 2018-12-20 | 2022-02-10 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| ES2997190T3 (en) | 2018-12-20 | 2025-02-14 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors |
| JP2023540270A (ja) * | 2020-08-28 | 2023-09-22 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| JP2024506329A (ja) * | 2021-02-09 | 2024-02-13 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| WO2022177917A2 (en) * | 2021-02-16 | 2022-08-25 | Theras, Inc. | Compositions and methods for inhibition of ras |
| WO2022184178A1 (en) * | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| IL308813A (en) * | 2021-06-10 | 2024-01-01 | Redx Pharma Plc | Quinazoline derivatives used as RAS inhibitors |
-
2023
- 2023-02-15 MX MX2024010045A patent/MX2024010045A/es unknown
- 2023-02-15 AU AU2023222076A patent/AU2023222076A1/en active Pending
- 2023-02-15 EP EP23711641.3A patent/EP4479401A1/en active Pending
- 2023-02-15 WO PCT/US2023/062687 patent/WO2023159086A1/en active Application Filing
- 2023-02-15 CN CN202380032897.3A patent/CN118974055A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118974055A (zh) | 2024-11-15 |
| AU2023222076A1 (en) | 2024-08-15 |
| EP4479401A1 (en) | 2024-12-25 |
| WO2023159086A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010045A (es) | Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras. | |
| MX2023012725A (es) | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. | |
| CO2023009083A2 (es) | Inhibidores de pan-kras de azaquinazolina | |
| CL2024003191A1 (es) | Compuestos de modulación de kras g12d | |
| CL2020002405A1 (es) | Inhibidores de kras g12c y métodos para su uso (divisional de la solicitud no. 201903394) | |
| MX2024010043A (es) | Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas kras mutantes. | |
| CO2022017049A2 (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
| ECSP088598A (es) | Derivados de piridazinona | |
| CY1121195T1 (el) | Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1 | |
| CL2022001513A1 (es) | Inhibidores de kras g12c | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| LTPA2016016I1 (lt) | Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui | |
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| CL2019001993A1 (es) | Inhibidores selectivos de jak1. | |
| CO6311051A2 (es) | Compuestos de pirimidina, composiciones y metodos de uso | |
| EA200700902A1 (ru) | 3-ариламинопиридиновые производные | |
| CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| MXPA05012573A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa. | |
| UY31017A1 (es) | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. | |
| ECSP22098041A (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| AR126849A1 (es) | Compuestos de quinazolina para tratamiento de enfermedad | |
| NZ813695A (en) | Parp1 inhibitors and uses thereof | |
| CO2023012342A2 (es) | Inhibidores de enzimas | |
| CO2024009144A2 (es) | Inhibidores de cinasa met |